JP2015524403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524403A5 JP2015524403A5 JP2015522106A JP2015522106A JP2015524403A5 JP 2015524403 A5 JP2015524403 A5 JP 2015524403A5 JP 2015522106 A JP2015522106 A JP 2015522106A JP 2015522106 A JP2015522106 A JP 2015522106A JP 2015524403 A5 JP2015524403 A5 JP 2015524403A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fusion protein
- domain
- functional fragment
- extracellular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 13
- 102000037865 fusion proteins Human genes 0.000 claims 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 5
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 5
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12176978.0 | 2012-07-18 | ||
| EP12176978 | 2012-07-18 | ||
| EP12176980.6 | 2012-07-18 | ||
| EP12176980 | 2012-07-18 | ||
| PCT/EP2013/065248 WO2014013037A1 (en) | 2012-07-18 | 2013-07-18 | Shortened cd95-fc variants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524403A JP2015524403A (ja) | 2015-08-24 |
| JP2015524403A5 true JP2015524403A5 (enExample) | 2016-08-12 |
| JP6317739B2 JP6317739B2 (ja) | 2018-04-25 |
Family
ID=48794121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015522107A Active JP6231562B2 (ja) | 2012-07-18 | 2013-07-18 | ＣＤ９５−Ｆｃアイソフォームの混合物を含む組成物 |
| JP2015522106A Expired - Fee Related JP6317739B2 (ja) | 2012-07-18 | 2013-07-18 | 短縮されたＣＤ９５−Ｆｃ変異体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015522107A Active JP6231562B2 (ja) | 2012-07-18 | 2013-07-18 | ＣＤ９５−Ｆｃアイソフォームの混合物を含む組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9434783B2 (enExample) |
| EP (4) | EP3409686B1 (enExample) |
| JP (2) | JP6231562B2 (enExample) |
| KR (1) | KR102201694B1 (enExample) |
| CN (3) | CN109897115A (enExample) |
| AU (2) | AU2013291984B2 (enExample) |
| BR (1) | BR112015000732B1 (enExample) |
| CA (2) | CA2878992C (enExample) |
| DK (2) | DK2875045T3 (enExample) |
| ES (2) | ES2674662T3 (enExample) |
| HK (1) | HK1207095A1 (enExample) |
| IL (1) | IL236659A (enExample) |
| MX (1) | MX371430B (enExample) |
| NZ (1) | NZ703546A (enExample) |
| RU (2) | RU2648157C2 (enExample) |
| SG (1) | SG11201500134QA (enExample) |
| UA (1) | UA116889C2 (enExample) |
| WO (2) | WO2014013037A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2875045T3 (en) * | 2012-07-18 | 2018-07-02 | Apogenix Ag | COMPOSITION comprising a mixture of CD95-FC ISOFORMs |
| AU2014261505B2 (en) * | 2013-04-29 | 2019-04-18 | Apogenix Ag | Method of diagnosing cancer |
| NO2776305T3 (enExample) * | 2014-04-23 | 2018-01-27 | ||
| WO2015165973A1 (en) | 2014-04-29 | 2015-11-05 | Apogenix Gmbh | Diagnostic anti-cd95l antibody |
| US9587215B2 (en) | 2014-08-07 | 2017-03-07 | General Electric Company | Devices, systems and methods for automated transfer of a sample |
| US20160176921A1 (en) * | 2014-12-22 | 2016-06-23 | Alexion Pharmaceuticals, Inc. | Methods of purifying recombinant proteins |
| KR20220002336A (ko) | 2019-03-29 | 2022-01-06 | 미스트 쎄라퓨틱스, 엘엘씨 | T 세포 치료제를 제조하기 위한 생체외 방법 및 관련 조성물 및 방법 |
| US20230032934A1 (en) | 2019-11-27 | 2023-02-02 | Myst Therapeutics, Llc | Method of producing tumor-reactive t cell composition using modulatory agents |
| CN114829371A (zh) * | 2019-12-12 | 2022-07-29 | Emd密理博公司 | 使用透析过滤缓冲液强化的病毒过滤 |
| CN115427438A (zh) | 2020-02-27 | 2022-12-02 | 迈斯特治疗公司 | 肿瘤反应性t细胞的离体富集和扩增的方法及其相关组合物 |
| CN115894706A (zh) * | 2021-09-30 | 2023-04-04 | 北京康辰药业股份有限公司 | 靶向PD-L1和FasL的融合蛋白、核苷酸序列及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2650597A (en) * | 1996-05-02 | 1997-11-26 | Mochida Pharmaceutical Co., Ltd. | Novel fas antigen derivatives |
| WO1998018487A1 (en) * | 1996-10-31 | 1998-05-07 | Mochida Pharmaceutical Co., Ltd. | Prophylactic/remedial agent |
| DE69839582D1 (de) * | 1997-02-27 | 2008-07-17 | Ono Pharmaceutical Co | Neues polypeptid, dafür kodierende dna und deren verwendungen |
| CA2309598A1 (en) * | 1997-11-10 | 1999-05-20 | Mochida Pharmaceutical Co., Ltd. | Preventives and remedies for diffuse lung disease |
| CN101684158A (zh) * | 2001-01-17 | 2010-03-31 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
| EP1273297A1 (en) * | 2001-07-06 | 2003-01-08 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Vitamin E for the treatment of diseases in which the binding of the transcription factor NF-KB and/or AP-1 to promoter target sites has a beneficial effect (eg AIDS, cardiac infarction) |
| PL1606318T3 (pl) | 2003-03-26 | 2010-01-29 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Ulepszone białka fuzyjne FC |
| AU2007231553B2 (en) * | 2006-03-28 | 2012-10-25 | Molecular Discovery Systems | Agent for the treatment of hormone-dependent disorders and uses thereof |
| ES2371287T3 (es) * | 2006-06-21 | 2011-12-29 | Apogenix Gmbh | Expresión diferencial de la citocina en cáncer humano. |
| US9309320B2 (en) * | 2006-12-28 | 2016-04-12 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo |
| WO2008101671A2 (en) * | 2007-02-19 | 2008-08-28 | Apogenix Gmbh | Il-4 fc fusion proteins |
| EP2009022A1 (en) * | 2007-06-26 | 2008-12-31 | Apogenix GmbH | Trimeric death ligands with enhanced activity (tenascin) |
| WO2010003766A2 (en) * | 2008-06-17 | 2010-01-14 | Apogenix Gmbh | Multimeric tnf receptors |
| EP2829550B1 (en) * | 2009-01-09 | 2016-11-16 | Apogenix AG | Fusion proteins forming trimers |
| CN102497886B (zh) * | 2009-07-21 | 2016-01-20 | 玛丽皇后与斯特菲尔德学院 | 用于细胞内药物递送的Fas(Apo-1，CD95)靶向平台 |
| JP2013512674A (ja) * | 2009-12-02 | 2013-04-18 | アクセルロン ファーマ， インコーポレイテッド | Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法 |
| DK2875045T3 (en) * | 2012-07-18 | 2018-07-02 | Apogenix Ag | COMPOSITION comprising a mixture of CD95-FC ISOFORMs |
| AU2014261505B2 (en) * | 2013-04-29 | 2019-04-18 | Apogenix Ag | Method of diagnosing cancer |
-
2013
- 2013-07-18 DK DK13742412.3T patent/DK2875045T3/en active
- 2013-07-18 CN CN201910254827.8A patent/CN109897115A/zh active Pending
- 2013-07-18 EP EP18164139.0A patent/EP3409686B1/en active Active
- 2013-07-18 CA CA2878992A patent/CA2878992C/en active Active
- 2013-07-18 BR BR112015000732-5A patent/BR112015000732B1/pt active IP Right Grant
- 2013-07-18 ES ES13742412.3T patent/ES2674662T3/es active Active
- 2013-07-18 CN CN201380043661.6A patent/CN104640876A/zh active Pending
- 2013-07-18 WO PCT/EP2013/065248 patent/WO2014013037A1/en not_active Ceased
- 2013-07-18 UA UAA201500254A patent/UA116889C2/uk unknown
- 2013-07-18 AU AU2013291984A patent/AU2013291984B2/en active Active
- 2013-07-18 CN CN201380038208.6A patent/CN104662039B/zh not_active Expired - Fee Related
- 2013-07-18 RU RU2015105328A patent/RU2648157C2/ru active
- 2013-07-18 AU AU2013291982A patent/AU2013291982B2/en not_active Ceased
- 2013-07-18 EP EP18166228.9A patent/EP3406630B1/en not_active Not-in-force
- 2013-07-18 WO PCT/EP2013/065250 patent/WO2014013039A1/en not_active Ceased
- 2013-07-18 RU RU2015105330A patent/RU2648146C2/ru active
- 2013-07-18 US US14/415,871 patent/US9434783B2/en not_active Expired - Fee Related
- 2013-07-18 KR KR1020157004183A patent/KR102201694B1/ko active Active
- 2013-07-18 JP JP2015522107A patent/JP6231562B2/ja active Active
- 2013-07-18 MX MX2015000731A patent/MX371430B/es active IP Right Grant
- 2013-07-18 EP EP13742412.3A patent/EP2875045B1/en active Active
- 2013-07-18 DK DK18164139.0T patent/DK3409686T3/da active
- 2013-07-18 US US14/415,866 patent/US9315570B2/en active Active
- 2013-07-18 ES ES18164139T patent/ES2924109T3/es active Active
- 2013-07-18 SG SG11201500134QA patent/SG11201500134QA/en unknown
- 2013-07-18 NZ NZ703546A patent/NZ703546A/en unknown
- 2013-07-18 EP EP13737631.5A patent/EP2875044B1/en not_active Not-in-force
- 2013-07-18 CA CA2877989A patent/CA2877989C/en not_active Expired - Fee Related
- 2013-07-18 JP JP2015522106A patent/JP6317739B2/ja not_active Expired - Fee Related
- 2013-07-18 HK HK15107778.6A patent/HK1207095A1/xx unknown
-
2015
- 2015-01-11 IL IL236659A patent/IL236659A/en active IP Right Grant
-
2016
- 2016-04-18 US US15/131,219 patent/US9657083B2/en active Active
- 2016-08-17 US US15/239,127 patent/US9908928B2/en active Active
-
2018
- 2018-02-22 US US15/902,175 patent/US10370441B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524403A5 (enExample) | ||
| JP2015525217A5 (enExample) | ||
| JP2015212284A5 (enExample) | ||
| HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
| PE20191033A1 (es) | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) | |
| EA201291362A1 (ru) | Слитый белок против злокачественных новообразований | |
| JP2012082206A5 (enExample) | ||
| WO2011123813A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| MX387465B (es) | Marcas genéticas de transgenes y métodos de uso. | |
| EP3372617A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
| BRPI1010880A2 (pt) | polipeptídeos de hormônio de crescimento e métodos de fazer e usar os mesmos. | |
| NZ602943A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| PE20190845A1 (es) | Metodos para determinar resistencia a terapia de receptor de androgeno | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| PH12012502272A1 (en) | Biological materials related to her3 | |
| WO2013151670A3 (en) | Modified polynucleotides for the production of nuclear proteins | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| JP2013527765A5 (enExample) | ||
| JP2015504052A5 (enExample) | ||
| EA201491277A1 (ru) | Противораковый слитый белок | |
| JP2018531624A5 (enExample) | ||
| PH12015500461A1 (en) | Novel il-17a binding molecules and medical uses thereof | |
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections | |
| EP2589658A4 (en) | PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN |